Recommending policy using unpublished data that has not yet been peer reviewed is problematic.

Last week, the National Toxicology Program (NTP) released part of a multi-year study designed to resolve debate over the safety of BPA.

Following the release of these partial data, the U.S. Food and Drug Administration (FDA) issued a statement characterizing the results as showing “minimal effects” from exposure to BPA, leading many to conclude that BPA is safe at current levels.

We believe, however, such conclusions are being drawn prematurely and without sufficient scientific evidence to support them.

The Consortium Linking Academic and Regulatory Insights on Bisphenol A Toxicity (CLARITY-BPA) study includes two separate investigations. The first (the FDA/NTP) relied on standard toxicology testing guidelines. This portion of the study – the one that has been released—is referred to as the core study.